Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
2024; Elsevier BV; Volume: 144; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2024-199152
ISSN1528-0020
AutoresYannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie‐Hélène Delfau‐Larue, Clémentine Sarkozy, Mary Callanan, Benoît Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine,
Tópico(s)Acute Myeloid Leukemia Research
Referência(s)